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Zusammenfassung
Hintergrund: Ziel dieser Arbeit war die Beurteilung des
aktuellen Managements der hautsparenden Mastektomie
an deutschen Krankenhäusern und die Hinterfragung der
onkologischen Sicherheit der Methode. Dazu wurden 100
Chirurgen bezüglich Ihres Vorgehens bei hautsparender
Mastektomie befragt. Ergebnisse: Fast alle Krankenhäu-
ser führen hautsparende Mastektomien durch, die meis-
ten in der Annahme, dass die Rezidivrate der der kon-
ventionellen Mastektomie entspricht. 95% der Kranken-
häuser bewerten das inflamatorische Karzinom als eine
Kontraindikation für die hautsparende Ablatio. Die meis-
ten Befragten resezieren, bis makroskopisch kein Drü-
sengewebe mehr vorhanden ist, und 73% belassen den
Mamillen-Areola-Komplex (MAK) auf der Grundlage von
Schnellschnittuntersuchungen. Der Volumenersatz er-
folgt meist mit einem Latissimus-dorsi-Myokutanflap
oder einem gestielten TRAM-Flap. In 79% der befragten
Krankenhäuser erfolgt die Rekonstruktion durch die gy-
näkologische Abteilung. Schlussfolgerungen: Die haut-
sparende Mastektomie wird als bestes kosmetisches
Rekonstruktionsverfahren in ausgewählten Patientinnen
mit Mammakarzinom angesehen. Der statistische Nach-
weis der onkologischen Sicherheit der Methode steht 
jedoch noch aus. Für die zukünftige Standardisierung der
für die hautsparende Mastektomie verwendeten chirurgi-
schen Techniken bedarf es der genauen Diskussion und
Evaluation.
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Summary
Background: The aim of this study was to evaluate the
current management of skin-sparing mastectomy in Ger-
man hospitals and to determine its oncologic safety. For
this purpose, 100 surgeons were surveyed regarding
their use of skin-sparing mastectomy. Results: Almost all
surveyed hospitals performed skin-sparing mastectomy.
Most of them believe that the recurrence rate is equal to
that of conventional mastectomy. 95% regard inflamma-
tory cancer as a contraindication to skin-sparing surgery.
Most of the hospitals thin out the skin without leaving
any macroscopic glandular tissue behind, and 73% leave
the nipple-areola complex (NAC) on the basis of frozen
sections. Volume replacement is most commonly done
with latissimus dorsi muscle flaps and pedicled TRAM
flaps. In 76% of the surveyed hospitals, reconstruction
after mastectomy is performed by the gynecological de-
partment. Conclusion: Skin-sparing mastectomy is con-
sidered to be the best cosmetic option for breast recon-
struction in selected breast cancer patients. At present,
statistical proof of its oncologic safety is lacking. The sur-
gical techniques used for skin-sparing mastectomy have
not yet been standardized. In order to achieve standard-
ization, careful discussion-making and evaluation remain
important.
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Introduction
Breast cancer is the most frequent malignant disease in
women in most parts of the world. Breast-conserving surgery
has been shown to be an oncologically sound strategy for
about 75% of patients, but more advanced stages of breast
cancer still require mastectomy. In these cases, skin-sparing
mastectomy, even with conservation of the nipple-areola com-
plex (NAC), is increasingly used. Recently published studies
support the use of the technique as an oncologically safe sur-
gical procedure attaining superior cosmetic results. The aim of
this study was to evaluate the management of skin-sparing
mastectomy in Germany.
Methods
We designed a questionnaire comprising 10 questions about skin-sparing
mastectomy. This included questions concerning the quantity and modali-
ty of skin-sparing mastectomy carried out in each hospital and the esti-
mated risk of recurrence compared to conventional mastectomy. The
questionnaires were sent to 100 randomly selected hospitals all over Ger-
many. 37 questionnaires were completed in full and sent back. 35 ques-
tionnaires were filled out in the course of an interview, 5 of them stem-
ming from university hospitals.
Results
The first skin-sparing mastectomy was performed in 1980 in
one of the surveyed hospitals. This is remarkable, since the
method was first described in 1991 by Thoth and Lappert [1].
3 clinics, including 2 university hospitals, share the highest fre-
quency with 60 operations per year. Remarkably, the lowest
frequency of 4 operations per year was also seen at a universi-
ty unit. Most of the clinics (85%) consider the local recurrence
rate of skin-sparing mastectomy to equal that of conventional
mastectomy. Only 9% describe the risk of local recurrence as
higher (fig. 1). 9 institutions base these statements on a review
of their own data demonstrating a specified local recurrence
rate between 0 and 8.3%. The median follow-up varied be-
tween 24 and 87 months, and the number of patients was a
minimum of 24 and a maximum of 120. Most of the hospitals
(97%) regard inflammatory cancer as a contraindication to
skin-sparing mastectomy, and 58% of them extend this to T4
cancer in general. Sporadically mentioned contraindications
include multicentricity (3 centers), planned radiation (2 cen-
ters), diffuse in situ components (2 centers) and central loca-
tion of the tumor (2 centers) (fig. 2).
Among the surveyed German hospitals, skin areas which are
being removed include at least the NAC in 59% and/or the
skin covering the tumor in 52%. Nevertheless, in 60% of cases,
a spindle incision around the NAC is also considered a thera-
peutic option. Another question concerned the thickness of
the remaining skin in skin-sparing mastectomy. None of the
centers entirely dissect the fatty tissue beyond the skin. 14
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centers stated measurement units. The average thickness was
8 mm with a range of 5–15 mm, but most of the hospitals dis-
sect the skin according to the macroscopic appearance. Thus,
83% thin out the skin without leaving any macroscopic glan-
dular tissue behind, while 13% require intraoperative exami-
0%
50%
100%
lower equal higer no comment
Fig. 1. Answers to the question: ‘How do you consider the local recur-
rence rate of skin-sparing mastectomy compared to conventional ma-
stectomy?’
0%
50%
100%
inflammatory cancer T4 cancer no contraindications
Fig. 2. Answers to the question: ‘What do you consider to be a con-
traindication for skin-sparing mastectomy?’
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50%
100%
never not in case of
DCIS
decision on
basis of frozen
section
always
Fig. 3. Answers to the question: ‘When do you preserve the nipple-are-
ola complex?’
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Fig. 4. Answers to the question: ‘What do you use for volume replace-
ment?’
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nation of frozen sections of randomly chosen parts of the sub-
cutis to help determine whether any microscopic breast
parenchyma has been left behind.
Skin-sparing mastectomy can also be modified to preserve the
NAC. 24% of the consulted hospitals never preserve the NAC,
whereas none of the hospitals preserve it in all cases. Most of
the clinics (75%) decide on the basis of frozen sections of the
subareolar margins. 18% remove the NAC in the case of ex-
tensive ductal carcinoma in-situ (DCIS) (fig. 3). 16% of the
clinics remove the NAC if the average distance to the primary
tumor is less than 2.75 cm. The specified range varies between
1 and 3 cm. On the question of volume replacement, 80% of
the surveyed hospitals use the latissimus dorsi muscle flap. In
72%, an additional skin area is dissected to gain more volume,
whereas in 40% no skin was involved. If necessary, 70% use
an implant in addition to the latissimus dorsi muscle flap. The
second most commonly used muscle flap is the TRAM (trans-
verse rectus abdominis muscle) flap, performed in 55% of hos-
pitals. The free TRAM flap and perforator flaps are per-
formed in only 6% of hospitals (fig. 4).
Neoadjuvant chemotherapy is common in a large number of
centers, but only a few hospitals (18%) operate within the new
borders of the tumor for tumor excision after chemotherapy.
Most centers still try to excise within the old borders. In this
case, 49% of the clinicians also use the skin-sparing mastecto-
my if necessary. Germany has a unique way of managing
breast cancer. In 79% of the surveyed German hospitals, re-
construction after mastectomy is performed by the gynecolog-
ical department, in 12% by the department of plastic surgery
and in 6% in collaboration between both.
Discussion
The loss of a breast is a traumatic event in a woman’s life, and
the beneficial effects of breast reconstruction on the psy-
chosocial and sexual well-being are proven [1–3]. The advan-
tage of skin-sparing mastectomy with immediate reconstruc-
tion by autotransplantation is associated with superior cos-
metic outcome. All other techniques produce more scarring.
The preserved breast skin forms an envelope and enhances
the esthetic results by providing nearly exact symmetry [4].
This is the reason why the technique of skin-sparing mastecto-
my is used by so many surgeons. Data have shown that the
oncologic safety with regard to local recurrence is comparable
to that of conventional mastectomy [5–17]. Table 1 shows an
overview of publications concerning this subject. Nevertheless,
statistical proof is still lacking. The local recurrence rate 10
years after conventional mastectomy is about 5% [18]. To
prove statistically that a new technique has an 80%-disadvan-
tage at the same level, 3,500 cases would have to be followed
up. Interestingly, no publication presents follow-up of more
than 565 cases. Thus, statistical evidence for oncologic reliabil-
ity is still outstanding.
Another problem is that skin-sparing mastectomy is not stan-
dardized. Most surgeons (83%) excise the skin until no more
glandular tissue is seen. It is evident that this does not lead to
skin that is free from glandular tissue. Those centers (13%)
performing intraoperative examination of frozen sections
along with the mastectomy procedure to determine whether
there is any glandular tissue left or not, can only make a state-
ment about the small areas of remaining skin from which the
biopsies were taken. Total glandular mastectomy and modi-
fied radical mastectomy (MRM) were compared by Barton et
al. [19] with respect to the amount of breast tissue remaining
after surgery. Multiple biopsies were taken from the anterior
chest wall of women following total glandular mastectomy and
MRM trying to detect any residual glandular tissue. Regard-
less of the procedure performed, breast tissue was histologi-
cally identified in 5% of all biopsy specimens. This implies that
mastectomy provides a percentile reduction of the glandular
tissue but never a complete removal. Excising the skin overly-
Reference Patients, Follow-up, LR, Conclusion
n months %
Newman et al. [6] 437 108 6.2 no significant increase
Hidalgo et al. [7] 28 27 0.0 no significant increase
Salvin et al. [8] 51 44.8 2.0 no significant increase
Kroll et al. [9] 114 >72 7.0 no significant increase
Toth et al. [10] 50 57 0.0 no significant increase
Simmons et al. [11] 77 15.6 3.9 no significant increase
Rivadeneira et al. [12] 71 49 5.6 no significant increase
Gerber et al. [13] 286 59 5.4 no significant increase
Peyser et al. [14] 71 24.1 3.0 no significant increase
Gheradini et al. [15] 31 20 0.0 no significant increase
Forster et al. [16] 67 49.2 4.0 no significant increase
Medina-Franco et al. [17] 173 73 4.5 no significant increase
Carlson et al. [18] 565 65.4 5.5 no systemic relapse
LR = Local recurrence rate.
Table 15. Publications concerning the local
recurrence rate of skin-sparing mastectomy
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ing the tumor, which is done in 52% of the surveyed hospitals,
is a way of reducing the risk of leaving behind glandular (es-
pecially malignant) tissue. A major concern involves the exci-
sion of the NAC which is removed in 59% of the clinics. How-
ever, several surgeons (60%) still remove skin around the
NAC using a spindle incision to imitate an MRM. The NAC is
one of the main characteristics of the female breast. There-
fore, it is obvious that there is great interest in preserving it.
Since all ducts end there, it is also obvious that leaving it be-
hind means leaving ductal tissue behind. This is a problem
particularly in cases of ductal and intraductal carcinomas. Our
data show that 18% of the centers remove the NAC in cases of
extensive DCIS. Most of the clinics (75%) base the decision to
preserve the NAC on intraoperative frozen sections. The his-
tological reliability of this method in the case of intraductal
carcinomas is dubious. Another way of making the decision is
to define the distance from the tumor. Nevertheless, this is
also just a statistical way of reducing the chance of leaving ma-
lignant tissue behind.
For volume replacement, the latissimus dorsi flap is the most
commonly used method (80%). This is due to the fact that it is
one of the safest flaps with regard to flap loss. Since the muscle
undergoes a certain degree of atrophy, most surgeons prefer to
take additional skin (72%) rather than just the muscle (40%).
The second most common flap is the TRAM flap which is used
in 55%. Only 6% of the surveyed German clinics use the mi-
crosurgical option of free TRAM flap and perforator flaps.
Whether this is due to the additional time or the microsurgical
skills required, could not be answered by the questionnaire.
But since 79% of reconstructive surgery after mastectomy are
performed by the department of gynecology, the lack of micro-
surgical training seems to be the major problem.
Neoadjuvant chemotherapy in breast cancer has been fre-
quently discussed over the last years. Only 18% of the hospi-
tals excise within the new borders of the tumor, although this
was recommended by the German Breast Cancer Group
(AGO) in the 2005 guidelines with an Oxford level of evi-
dence 3b determined by individual case control studies. Most
surgeons still try to excise within the old borders, but the ques-
tion remains of how to find the old borders after chemothera-
py. Therefore, 49% of the surveyed hospitals use skin-sparing
mastectomy after neoadjuvant chemotherapy if necessary.
Conclusion
Skin-sparing mastectomy is the best cosmetic option for im-
mediate breast reconstruction. Statistical proof of its oncolog-
ic safety is still lacking. It has been shown that small amounts
of glandular tissue are left behind by MRM. Logically, leaving
behind more skin means leaving behind more glandular tis-
sue. Keeping this in mind, it is important to examine the local
recurrence rate. For this purpose, at least 3,500 cases of skin-
sparing mastectomy will have to be monitored. Currently, the
methods of skin-sparing mastectomy are not standardized.
Hence, careful discussion and evaluation remain important to
standardize the surgical techniques so that comparable results
can be obtained. Questions that remain include: Which skin
areas should be removed? How thick should the remaining
skin be? Is it safe to thin out the skin to the point that no
macroscopic glandular tissue is left or to consider the micro-
scopic aspect by performing a frozen section? Is it oncologi-
cally safe to preserve the NAC? Overall multicenter studies
are needed to answer these questions.
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